Table 3. Detailed treatments of each group in the xenograft model.
| Group (5 nude mice) | Cells inoculated | CDDP (2 mg/kg) | NS | Luteolin (5 mg/kg) |
|---|---|---|---|---|
| OEVRK1-Ec9706+CDDP | OEVRK1 -Ec9706 | + | - | - |
| OEVRK1-Ec9706+NS | - | + | - | |
| shVRK1-Ec9706+CDDP | shVRK1-Ec9706 | + | - | - |
| shVRK1-Ec9706+NS | - | + | - | |
| Blank-Ec9706+CDDP | Blank-Ec9706 | + | - | - |
| Blank-Ec9706+NS | - | + | - | |
| Blank-Ec9706+CDDP+Luteolin | + | - | + | |
| Blank-Ec9706+NS+Luteolin | - | + | + |
Abbreviations: VRK1, vaccinia related kinase 1; CDDP, cisplatin; NS, normal saline; OEVRK1-Ec9706, Ec9706 stably overexpressing VRK1; shVRK1-Ec9706, Ec9706 cells stably expressing VRK1-shRNA.